These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20806114)

  • 1. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma.
    Samama MM; Amiral J; Guinet C; Perzborn E; Depasse F
    Thromb Haemost; 2010 Nov; 104(5):1078-9. PubMed ID: 20806114
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study.
    Tripodi A; Chantarangkul V; Guinet C; Samama MM
    J Thromb Haemost; 2011 Jan; 9(1):226-8. PubMed ID: 20942848
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
    Barrett YC; Wang Z; Frost C; Shenker A
    Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facts and artefacts of coagulation assays for factor Xa inhibitors.
    Haas S
    Thromb Haemost; 2010 Apr; 103(4):686-8. PubMed ID: 20174751
    [No Abstract]   [Full Text] [Related]  

  • 6. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban.
    Harenberg J; Marx S; Weiss C; Krämer R; Samama M; Schulman S;
    J Thromb Haemost; 2012 Jul; 10(7):1433-6. PubMed ID: 22947062
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
    Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
    Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.
    Komotar RJ; Starke RM; Connolly ES
    Neurosurgery; 2008 Oct; 63(4):N10-1. PubMed ID: 18981864
    [No Abstract]   [Full Text] [Related]  

  • 9. Determination of rivaroxaban in human plasma samples.
    Harenberg J; Erdle S; Marx S; Krämer R
    Semin Thromb Hemost; 2012 Mar; 38(2):178-84. PubMed ID: 22422332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.
    Hillarp A; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Lindahl TL
    J Thromb Haemost; 2011 Jan; 9(1):133-9. PubMed ID: 20946166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions.
    Mani H; Hesse C; Stratmann G; Lindhoff-Last E
    Thromb Haemost; 2013 Jan; 109(1):127-36. PubMed ID: 23138190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.
    Samama MM; Contant G; Spiro TE; Perzborn E; Guinet C; Gourmelin Y; Le Flem L; Rohde G; Martinoli JL;
    Thromb Haemost; 2012 Feb; 107(2):379-87. PubMed ID: 22187012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays.
    Tichelaar V; de Jong H; Nijland H; Kluin-Nelemans H; Meijer K; Mulder A
    Thromb Haemost; 2011 Nov; 106(5):990-2. PubMed ID: 21901233
    [No Abstract]   [Full Text] [Related]  

  • 14. Correlating prothrombin time with plasma rivaroxaban level.
    Rodgers R; Bagot CN; Lawrence C; Hickman G; McGurk M; Tait RC
    Br J Haematol; 2013 Dec; 163(5):685-7. PubMed ID: 24219334
    [No Abstract]   [Full Text] [Related]  

  • 15. Rivaroxaban: a new oral factor Xa inhibitor.
    Perzborn E; Roehrig S; Straub A; Kubitza D; Mueck W; Laux V
    Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):376-81. PubMed ID: 20139357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories.
    Asmis LM; Alberio L; Angelillo-Scherrer A; Korte W; Mendez A; Reber G; Seifert B; Stricker H; Tsakiris DA; Wuillemin WA
    Thromb Res; 2012 Apr; 129(4):492-8. PubMed ID: 21840043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rivaroxaban and factor Xa inhibitors in clinical practice].
    Penka M
    Vnitr Lek; 2010 Sep; 56(9):920-6. PubMed ID: 21137179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor Xa inhibitors: today and beyond.
    Walenga JM; Jeske WP; Hoppensteadt D; Fareed J
    Curr Opin Investig Drugs; 2003 Mar; 4(3):272-81. PubMed ID: 12735228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the factor Xa inhibitor rivaroxaban on arterial thrombosis in wild-type and apolipoprotein E-deficient mice.
    Wagner NM; Dressel T; Schäfer K; Konstantinides S
    Thromb Res; 2012 Nov; 130(5):793-8. PubMed ID: 22281071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin.
    Mani H; Rohde G; Stratmann G; Hesse C; Herth N; Schwers S; Perzborn E; Lindhoff-Last E
    Thromb Haemost; 2012 Jul; 108(1):191-8. PubMed ID: 22534775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.